

					COMPLETE IF KNOWN			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					<b>U.S. PATENT DOCUMENTS</b>			
Examiner Initials*	Cite No.	Form PTO-1449 (Modified) Use several sheets if necessary (Kind Code (if known))			Number 09/493,427			
					Confirmation Number 2225			
					Filing Date January 29, 2000			
					First Named Inventor Iversen et al.			
					Filing Date of Cited Document 1680			
Name of Patentee or Applicant of Cited Document					Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
Epstein et al.					13/10/00			
Attorney Docket No.					50450-8025.US00			
<b>FOREIGN PATENT DOCUMENTS</b>								
Examiner Initials*	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				
<b>OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS</b>								
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.						T

EXAMINER 	DATE CONSIDERED 3-28-06
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).	

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO-1449 (Modified) (Use several sheets if necessary)			<b>COMPLETE IF KNOWN</b>		
			Application Number	09/493,427	
			Confirmation Number	2225	
			Filing Date	January 29, 2000	
			First Named Inventor	Iversen et al.	
			Group Art Unit	1633	
Sheet	1	of	1	Examiner Name	Epps-Ford, J.
				Attorney Docket No.	50450-8025.US00

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent or Application		Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear
		NUMBER	Kind Code			
*						

FOREIGN PATENT DOCUMENTS								
Examiner Initial	Cite No.	Foreign Patent or Application			Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Figures Appear	T
		Office	NUMBER	Kind Code (if known)				

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	T
		Kutryk, M. et al., "Local Intracoronary Administration of Antisense Oligonucleotide Against c-myc for the Prevention of In-Stent Restenosis", <i>Journal of the American College of Cardiology</i> 39(2):281-287, 2002.	
		Bult, Hidde, "Restenosis: a challenge for pharmacology", <i>TIPS</i> 21:274-279, 2000.	
		Kent, K. and Liu, B., "Intimal Hyperplasia – Still Here after All These Years!", <i>Annals of Vascular Surgery, Inc.</i> 18(2):135-137, 2004.	
		Roqué, F. et al., "Safety of Intracoronary Administration of c-myc Antisense Oligomers After Percutaneous Transluminal Coronary Angioplasty (PTCA)", <i>Antisense &amp; Nucleic Acid Drug Development</i> 11:99-106, 2001.	
		Gruberg, L. et al., "Novel approaches for the prevention of restenosis", <i>Exp. Opin. Invest. Drugs</i> 9(11):2555-2578, 2000.	

EXAMINER		DATE CONSIDERED	3-28-06
*EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application(s).			